Piper ups Neurocrine to overweight, says 568 still in the game

NBIX Stock  USD 127.01  0.16  0.13%   
Slightly above 55% of Neurocrine Biosciences' investor base is interested to short. The analysis of the overall investor sentiment regarding Neurocrine Biosciences suggests that many traders are impartial. Neurocrine Biosciences' investing sentiment can be driven by a variety of factors including economic data, Neurocrine Biosciences' earnings reports, geopolitical events, and overall market trends.
  
Piper Sandler upgraded Neurocrine Biosciences to overweight, stating it sees the companys schizophrenia drug NBI-1117568 as still in the game despite recent data.

Read at seekingalpha.com
seekingalpha News
  

Neurocrine Biosciences Current Investor Sentiment

Panic Vs Confidence

45

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Neurocrine Biosciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Neurocrine Biosciences.

Neurocrine Biosciences Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Neurocrine Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neurocrine Biosciences Historical Investor Sentiment

Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neurocrine Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neurocrine Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neurocrine Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Neurocrine Biosciences.

Neurocrine Biosciences Fundamental Analysis

We analyze Neurocrine Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Neurocrine Biosciences is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Neurocrine Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurocrine Biosciences stock to make a market-neutral strategy. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with similar companies.

Peers

Neurocrine Biosciences Related Equities

SUPNSupernus Pharmaceuticals   3.33   
0%
17.0%
PBHPrestige Brand   0.15   
1.0%
0%
DVAXDynavax Technologies   1.17   
6.0%
0%
ANIPANI Pharmaceuticals   1.20   
6.0%
0%
AMPHAmphastar   1.77   
9.0%
0%
COLLCollegium Pharmaceutical   2.39   
12.0%
0%
ALKSAlkermes Plc   2.83   
14.0%
0%
ITCIIntracellular   3.36   
17.0%
0%
PCRXPacira BioSciences,   4.00   
20.0%
0%
IRWDIronwood Pharmaceuticals   8.16   
42.0%
0%
EVOEvotec SE   8.83   
45.0%
0%
AVDLAvadel Pharmaceuticals   19.33   
100.0%
0%

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.